BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2959047)

  • 1. Thromboxane biosynthesis and antagonism in humans.
    FitzGerald GA; Fitzgerald DJ; Lawson JA; Murray R
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():199-203. PubMed ID: 2959047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thromboxane antagonism in thrombocytes--pathophysiology, pharmacology and possible clinical significance].
    Schrör K
    Wien Klin Wochenschr; 1991; 103(18):543-53. PubMed ID: 1836294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane A2 biosynthesis in human disease.
    FitzGerald GA; Healy C; Daugherty J
    Fed Proc; 1987 Jan; 46(1):154-8. PubMed ID: 3100340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of physiological and pathophysiological effects of thromboxane A2.
    Ogletree ML
    Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibitors?
    Smith EF
    Eicosanoids; 1989; 2(4):199-212. PubMed ID: 2534279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thromboxane A2 and prevention of cardiovascular diseases].
    Schrör K
    Z Kardiol; 1992; 81 Suppl 4():185-9. PubMed ID: 1290297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 10. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
    Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
    J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.
    Vezza R; Spina D; Tallarida RJ; Nathan M; Page CP; Gresele P
    Thromb Haemost; 1997 Nov; 78(5):1385-91. PubMed ID: 9408024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboxane biosynthesis in cardiovascular diseases.
    Patrono C; Ciabattoni G; Davi G
    Stroke; 1990 Dec; 21(12 Suppl):IV130-3. PubMed ID: 2260137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboxane synthesis inhibitors and receptor antagonists.
    Patrono C
    Thromb Res Suppl; 1990; 11():15-23. PubMed ID: 2148990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
    Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
    Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E; Belogi L; Mezzadri CM
    Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.